BioHive is a biotech company building next-generation human skin biobanks and organoid platforms to transform preclinical research. At the core of its approach, BioHive develops and structures access to diverse, patient-derived skin samples, enabling the generation of in vitro models that capture the full spectrum of human skin biology, including different skin types, ethnic backgrounds, and disease states.

Leveraging this unique biological foundation, BioHive engineers advanced 3D skin organoids that reproduce key structural, cellular, and functional features of human skin. These platforms integrate multiple cell types and disease-relevant components to enable highly predictive studies of efficacy, mechanism of action, biomarker discovery, and safety.

By combining patient-derived biobanks, tissue engineering, multi-omics, and advanced imaging, BioHive delivers translatable, human-relevant data that addresses the limitations of conventional models. Positioned at the forefront of new approach methodologies (NAMs), BioHive supports pharmaceutical and biotech partners in de-risking development, accelerating decision-making, and enabling more precise and effective therapies.